Efficacy and Safety of Canagliflozin 300 mg in Overweight and Obese Type 2 Diabetes Mellitus Patients in a Real-world Setting: COLOR Study.

Aneja, Pankaj; Bhalla, Gaurav; Parvesh, Neeti; Aneja, Kunal; Aneja, Kashish

Aneja, Pankaj; Bhalla, Gaurav; Parvesh, Neeti; Aneja, Kunal; Aneja, Kashish.

Afiliação

Aneja P; Department of Diabetes and Metabolic Disorders, Care and Cure, New Delhi, India.
Bhalla G; Department of Diabetes and Metabolic Disorders, The Specialist Clinic, New Delhi, India.
Parvesh N; Department of Diabetes and Metabolic Disorders, Kanishka Health Care, New Delhi, India.
Aneja K; Department of Orthopaedics, Care and Cure, New Delhi, India.
Aneja K; BA, LLB (HONS), New Delhi, India.

Indian J Endocrinol Metab ; 23(3): 307-311, 2019.

Article em En | MEDLINE | ID: mdl-31641632

Palavras-chave

Canagliflozin; HbA1c; India; obese; type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Indian J Endocrinol Metab Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Índia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google